+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020

  • ID: 5007692
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 37 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020, provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

Proliferative Vitreoretinopathy (PVR) occurs when a scar forms under or on the retina after retinal detachment, preventing the retina from healing and falling back into place. Risk factors for proliferative vitreoretinopathy include bleeding within the eye, increased inflammation from trauma, high degree myopia (short-sightedness), family history, severe inflammation or complications from diabetes.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Proliferative Vitreoretinopathy (PVR) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Vitreoretinopathy (PVR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Proliferative Vitreoretinopathy (PVR) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Vitreoretinopathy (PVR) (Ophthalmology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Proliferative Vitreoretinopathy (PVR) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • MORE
  • Introduction
  • Report Coverage
  • Proliferative Vitreoretinopathy (PVR) - Overview
  • Proliferative Vitreoretinopathy (PVR) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Proliferative Vitreoretinopathy (PVR) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Proliferative Vitreoretinopathy (PVR) - Companies Involved in Therapeutics Development
  • Aldeyra Therapeutics Inc
  • Aptitude Medical Systems Inc
  • F. Hoffmann-La Roche Ltd
  • Focal Point Pharmaceuticals Inc
  • Novartis AG
  • Proliferative Vitreoretinopathy (PVR) - Drug Profiles
  • Aptamers to Inhibit PDGF for Proliferative Vitreoretinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • methotrexate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OM-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PRM-167 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Hdm2 for Proliferative Vitreoretinopathy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • XOMA-089 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proliferative Vitreoretinopathy (PVR) - Dormant Projects
  • Proliferative Vitreoretinopathy (PVR) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 24, 2020: Aldeyra Therapeutics provides update on its proliferative vitreoretinopathy drug candidate at 2020 Research & Development Day
  • Dec 20, 2019: Aldeyra Therapeutics enrols first patient in Phase III GUARD study
  • Sep 24, 2019: Aldeyra Therapeutics receives Fast Track Designation for ADX-2191 for the prevention of Proliferative Vitreoretinopathy
  • May 07, 2012: Promedior Presents Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
  • May 01, 2012: Promedior To Present Preclinical Data Of Pentraxin-2 At ARVO Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Aptitude Medical Systems Inc, H1 2020
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Focal Point Pharmaceuticals Inc, H1 2020
  • Proliferative Vitreoretinopathy (PVR) - Pipeline by Novartis AG, H1 2020
  • Proliferative Vitreoretinopathy (PVR) - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Proliferative Vitreoretinopathy (PVR), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aldeyra Therapeutics Inc
  • Aptitude Medical Systems Inc
  • F. Hoffmann-La Roche Ltd
  • Focal Point Pharmaceuticals Inc
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll